Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.

Carpenter C, Zestos AG, Altshuler R, Sorenson RJ, Guptaroy B, Showalter HD, Kennedy RT, Jutkiewicz E, Gnegy ME.

Neuropsychopharmacology. 2017 Sep;42(10):1940-1949. doi: 10.1038/npp.2017.95. Epub 2017 May 11.

PMID:
28492278
2.

Tamoxifen and its active metabolites inhibit dopamine transporter function independently of the estrogen receptors.

Mikelman SR, Guptaroy B, Gnegy ME.

J Neurochem. 2017 Apr;141(1):31-36. doi: 10.1111/jnc.13955. Epub 2017 Feb 14.

3.

Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?

Mikelman S, Mardirossian N, Gnegy ME.

J Chem Neuroanat. 2017 Oct;83-84:50-58. doi: 10.1016/j.jchemneu.2016.08.004. Epub 2016 Aug 30. Review.

PMID:
27585851
4.

PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux.

Zestos AG, Mikelman SR, Kennedy RT, Gnegy ME.

ACS Chem Neurosci. 2016 Jun 15;7(6):757-66. doi: 10.1021/acschemneuro.6b00028. Epub 2016 Mar 28.

5.

Individual variation in incentive salience attribution and accumbens dopamine transporter expression and function.

Singer BF, Guptaroy B, Austin CJ, Wohl I, Lovic V, Seiler JL, Vaughan RA, Gnegy ME, Robinson TE, Aragona BJ.

Eur J Neurosci. 2016 Mar;43(5):662-70. doi: 10.1111/ejn.13134. Epub 2016 Jan 7.

6.

Protein kinase C beta regulates the D₂-like dopamine autoreceptor.

Luderman KD, Chen R, Ferris MJ, Jones SR, Gnegy ME.

Neuropharmacology. 2015 Feb;89:335-41.

7.

An N-terminal threonine mutation produces an efflux-favorable, sodium-primed conformation of the human dopamine transporter.

Fraser R, Chen Y, Guptaroy B, Luderman KD, Stokes SL, Beg A, DeFelice LJ, Gnegy ME.

Mol Pharmacol. 2014 Jul;86(1):76-85. doi: 10.1124/mol.114.091926. Epub 2014 Apr 21.

8.

Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism.

Bosse KE, Jutkiewicz EM, Schultz-Kuszak KN, Mabrouk OS, Kennedy RT, Gnegy ME, Traynor JR.

Neuropharmacology. 2014 Feb;77:19-27. doi: 10.1016/j.neuropharm.2013.08.027. Epub 2013 Sep 10.

9.

Amphetamine stimulates movement through thalamocortical glutamate release.

Mabrouk OS, Semaan DZ, Mikelman S, Gnegy ME, Kennedy RT.

J Neurochem. 2014 Jan;128(1):152-61. doi: 10.1111/jnc.12378. Epub 2013 Aug 19.

10.

Protein kinase Cβ is a modulator of the dopamine D2 autoreceptor-activated trafficking of the dopamine transporter.

Chen R, Daining CP, Sun H, Fraser R, Stokes SL, Leitges M, Gnegy ME.

J Neurochem. 2013 Jun;125(5):663-72. doi: 10.1111/jnc.12229. Epub 2013 Mar 18.

11.

Leptin action via neurotensin neurons controls orexin, the mesolimbic dopamine system and energy balance.

Leinninger GM, Opland DM, Jo YH, Faouzi M, Christensen L, Cappellucci LA, Rhodes CJ, Gnegy ME, Becker JB, Pothos EN, Seasholtz AF, Thompson RC, Myers MG Jr.

Cell Metab. 2011 Sep 7;14(3):313-23. doi: 10.1016/j.cmet.2011.06.016.

12.

Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters.

Guptaroy B, Fraser R, Desai A, Zhang M, Gnegy ME.

Mol Pharmacol. 2011 Mar;79(3):520-32. doi: 10.1124/mol.110.069039. Epub 2010 Dec 13.

13.
14.

PKCbeta co-localizes with the dopamine transporter in mesencephalic neurons.

O'Malley HA, Park Y, Isom LL, Gnegy ME.

Neurosci Lett. 2010 Aug 9;480(1):40-3.

15.

Leptin promotes dopamine transporter and tyrosine hydroxylase activity in the nucleus accumbens of Sprague-Dawley rats.

Perry ML, Leinninger GM, Chen R, Luderman KD, Yang H, Gnegy ME, Myers MG Jr, Kennedy RT.

J Neurochem. 2010 Aug;114(3):666-74. doi: 10.1111/j.1471-4159.2010.06757.x. Epub 2010 Apr 20.

16.

Dopamine transporter trafficking: rapid response on demand.

Chen R, Furman CA, Gnegy ME.

Future Neurol. 2010 Jan 1;5(1):123.

17.

Rab 11 regulates constitutive dopamine transporter trafficking and function in N2A neuroblastoma cells.

Furman CA, Lo CB, Stokes S, Esteban JA, Gnegy ME.

Neurosci Lett. 2009 Sep 29;463(1):78-81. doi: 10.1016/j.neulet.2009.07.049. Epub 2009 Jul 22.

18.

Conditional ablation and recovery of forebrain neurogenesis in the mouse.

Singer BH, Jutkiewicz EM, Fuller CL, Lichtenwalner RJ, Zhang H, Velander AJ, Li X, Gnegy ME, Burant CF, Parent JM.

J Comp Neurol. 2009 Jun 20;514(6):567-82. doi: 10.1002/cne.22052.

19.

Protein kinase Cbeta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice.

Chen R, Furman CA, Zhang M, Kim MN, Gereau RW 4th, Leitges M, Gnegy ME.

J Pharmacol Exp Ther. 2009 Mar;328(3):912-20. doi: 10.1124/jpet.108.147959. Epub 2008 Dec 19.

20.

A juxtamembrane mutation in the N terminus of the dopamine transporter induces preference for an inward-facing conformation.

Guptaroy B, Zhang M, Bowton E, Binda F, Shi L, Weinstein H, Galli A, Javitch JA, Neubig RR, Gnegy ME.

Mol Pharmacol. 2009 Mar;75(3):514-24. doi: 10.1124/mol.108.048744. Epub 2008 Dec 19.

21.

Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux.

Binda F, Dipace C, Bowton E, Robertson SD, Lute BJ, Fog JU, Zhang M, Sen N, Colbran RJ, Gnegy ME, Gether U, Javitch JA, Erreger K, Galli A.

Mol Pharmacol. 2008 Oct;74(4):1101-8. doi: 10.1124/mol.108.048447. Epub 2008 Jul 10.

22.

The selective delta opioid agonist SNC80 enhances amphetamine-mediated efflux of dopamine from rat striatum.

Bosse KE, Jutkiewicz EM, Gnegy ME, Traynor JR.

Neuropharmacology. 2008 Oct;55(5):755-62. doi: 10.1016/j.neuropharm.2008.06.017. Epub 2008 Jun 18.

23.

Nicotine and amphetamine acutely cross-potentiate their behavioral and neurochemical responses in female Holtzman rats.

Jutkiewicz EM, Nicolazzo DM, Kim MN, Gnegy ME.

Psychopharmacology (Berl). 2008 Sep;200(1):93-103. doi: 10.1007/s00213-008-1159-y. Epub 2008 Jun 20.

PMID:
18566803
24.

C57BL/6J mice show greater amphetamine-induced locomotor activation and dopamine efflux in the striatum than 129S2/SvHsd mice.

Chen R, Zhang M, Park S, Gnegy ME.

Pharmacol Biochem Behav. 2007 May;87(1):158-63. Epub 2007 May 4.

25.

Simple transporter trafficking model for amphetamine-induced dopamine efflux.

Thwar PK, Guptaroy B, Zhang M, Gnegy ME, Burns MA, Linderman JJ.

Synapse. 2007 Jul;61(7):500-14.

26.

Rapid delivery of the dopamine transporter to the plasmalemmal membrane upon amphetamine stimulation.

Johnson LA, Furman CA, Zhang M, Guptaroy B, Gnegy ME.

Neuropharmacology. 2005 Nov;49(6):750-8. Epub 2005 Oct 5.

PMID:
16212991
27.

Regulation of amphetamine-stimulated dopamine efflux by protein kinase C beta.

Johnson LA, Guptaroy B, Lund D, Shamban S, Gnegy ME.

J Biol Chem. 2005 Mar 25;280(12):10914-9. Epub 2005 Jan 12.

28.

Repeated amphetamine couples norepinephrine transporter and calcium channel activities in PC12 cells.

Kantor L, Zhang M, Guptaroy B, Park YH, Gnegy ME.

J Pharmacol Exp Ther. 2004 Dec;311(3):1044-51. Epub 2004 Aug 30.

29.

Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter.

Gnegy ME, Khoshbouei H, Berg KA, Javitch JA, Clarke WP, Zhang M, Galli A.

Mol Pharmacol. 2004 Jul;66(1):137-43.

30.

N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux.

Khoshbouei H, Sen N, Guptaroy B, Johnson L', Lund D, Gnegy ME, Galli A, Javitch JA.

PLoS Biol. 2004 Mar;2(3):E78. Epub 2004 Mar 16.

32.

The effect of phosphorylation on amphetamine-mediated outward transport.

Gnegy ME.

Eur J Pharmacol. 2003 Oct 31;479(1-3):83-91. Review.

PMID:
14612140
33.

Cytochrome c translocation does not lead to caspase activation in maitotoxin-treated SH-SY5Y neuroblastoma cells.

McGinnis KM, Gnegy ME, Falk N, Nath R, Wang KK.

Neurochem Int. 2003 May;42(6):517-23.

PMID:
12547651
34.
35.

Ca2+/calmodulin signaling in NMDA-induced synaptic plasticity.

Gnegy ME.

Crit Rev Neurobiol. 2000;14(2):91-129. Review.

PMID:
11513244
36.

Caspase-mediated calcineurin activation contributes to IL-2 release during T cell activation.

Mukerjee N, McGinnis KM, Gnegy ME, Wang KK.

Biochem Biophys Res Commun. 2001 Aug 3;285(5):1192-9.

PMID:
11478781
37.

Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells.

Kantor L, Hewlett GH, Park YH, Richardson-Burns SM, Mellon MJ, Gnegy ME.

J Pharmacol Exp Ther. 2001 Jun;297(3):1016-24.

38.
39.

Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells.

Mukerjee N, McGinnis KM, Park YH, Gnegy ME, Wang KK.

Arch Biochem Biophys. 2000 Jul 15;379(2):337-43.

PMID:
10898953
41.

Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes.

Cowell RM, Kantor L, Hewlett GH, Frey KA, Gnegy ME.

Eur J Pharmacol. 2000 Feb 11;389(1):59-65.

PMID:
10686296
42.

Procaspase-3 and poly(ADP)ribose polymerase (PARP) are calpain substrates.

McGinnis KM, Gnegy ME, Park YH, Mukerjee N, Wang KK.

Biochem Biophys Res Commun. 1999 Sep 16;263(1):94-9.

PMID:
10486259
44.
46.
47.

Injection of the protein kinase C inhibitor Ro31-8220 into the nucleus accumbens attenuates the acute response to amphetamine: tissue and behavioral studies.

Browman KE, Kantor L, Richardson S, Badiani A, Robinson TE, Gnegy ME.

Brain Res. 1998 Dec 14;814(1-2):112-9.

PMID:
9838071
48.

Alterations in calmodulin mRNA expression and calmodulin content in rat brain after repeated, intermittent amphetamine.

Michelhaugh SK, Pimputkar G, Gnegy ME.

Brain Res Mol Brain Res. 1998 Nov 12;62(1):35-42.

PMID:
9795121
49.
50.

The effect of environment on the changes in calmodulin in rat brain produced by repeated amphetamine treatment.

Ostrander MM, Hartman J, Badiani A, Robinson TE, Gnegy ME.

Brain Res. 1998 Jun 29;797(2):339-41.

PMID:
9666166

Supplemental Content

Loading ...
Support Center